CARNALL FARRAR LTD

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  -25.2%

  £15,076,463 → £11,277,196

  lowest in 5 filed years

• Cash

  -100%

  £393,774 → £134

  lowest in 9 filed years

• Net assets

  -23.1%

  £1,280,887 → £985,363

  lowest in 5 filed years

• Employees

  -14.1%

  78 → 67

• Operating profit

  +7.1%

  £261,814 → £280,477

• Profit before tax

  +9.7%

  £213,811 → £234,531

• Wages

  +4%

  £5,638,073 → £5,862,419

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

HaysMac LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.”

Significant events

• “Launched the Federated Data Platform (FDP) consortium, supporting trusts to standardise data and adopt the latest innovations to improve patient care across NHS”
• “Partnering with national and regional healthcare organisations to drive strategic transformation and deliver financial improvement, inform the NHS 10-Year Plan, and help regions restructure their operating models for effective delivery”
• “Delivering transformative projects for leading life science and pharmaceutical companies, establishing our expertise in health equity, data, and digital transformation, and building deep capabilities in bridging scientific innovation with real-world implementation”
• “Extending our impact into the charitable sector, partnering with organisations to publish critical reports to help shape national policy”
• “Building momentum in our newly established health investing practice, with a leading private sector player partnering with us on a variety of projects, including commercial due diligence, baseline impact assessment and reconfiguration of sites”
• “Appointed Catherine Skilton, Managing Partner for Health Systems, to support growth and innovation across Financial and Performance Improvement service lines”
• “Appointed Dr Joud Abduljawad, as Partner and Chief Medical Officer for the Middle East”
• “Appointed Vernon Baxter as Associate Partner for Health Investing, deepening our expertise in the private healthcare market to complement our growth ambitions”
• “Launched our subsidiary company in the Middle East, to achieve our ambition on supporting healthcare on a global scale”
• “Invested in our corporate capabilities and infrastructure to prepare us for growth, including strengthening of our People, Commercial and Business Development functions.”
• “Headline turnover has declined since 2024 as part of a deliberate strategy to prioritise revenue generation through our own workforce rather than subcontractors. This approach has driven an improvement in gross profit margin and continues to be executed throughout 2025/26.”
• “There have been no significant events affecting the Company since the year end.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

7

last 12 months

Capital events

4

last 24 months

Officers appointed

1

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.